persrero.tk

Paclitaxel-eluting platinum chromium coronary stent system

2020-01-20 01:34

Apr 25, 2011 Boston Scientific launches ION PaclitaxelEluting Platinum Chromium Coronary Stent System. The ION Stent is backed by the proven safety and efficacy of the TAXUS clinical program, which spans 10 years of research in nearly 50, 000 patients in 28 pre and postmarket studies.ION PaclitaxelEluting. Platinum Chromium Coronary Stent System. Indications, Safety, and Warnings. Return to Product Page. CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete Directions for Use for more information on Indications, Contraindications paclitaxel-eluting platinum chromium coronary stent system

FDA approves ION Platinum Chromium stent system. Outside the US, including CE mark countries where it was approved in May 2010, the ION stent system is commercialised as the Taxus Element PaclitaxelEluting coronary stent system. The ION stent is backed by the proven safety and efficacy of the TAXUS clinical programme,

Jun 19, 2013  Platinum chromium (PtCr) Element stent platform. The Element stent was designed utilizing the improved mechanical properties and radiopacity of the platinumenhanced alloy. The stent platform consists of 33 iron, 33 platinum, 18 chromium, 9 nickel, 3 molybdenum, and a How can the answer be improved? paclitaxel-eluting platinum chromium coronary stent system PaclitaxelEluting Platinum Chromium Coronary Stent System. The ION Stent combines the consistent and proven clinical performance of Paclitaxel with the exceptional visibility, strength, and flexibility of our PtCr platform.

Biologics: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW A novel platinum chromium everolimuseluting stent for the treatment of coronary artery disease Johan Bennett Abstract: The development of coronary stents represents a major step forward in the treatment of Christophe Dubois obstructive coronary artery disease since paclitaxel-eluting platinum chromium coronary stent system In the U. S. , the TAXUS Element Stent System will be commercialized as the ION PaclitaxelEluting Platinum Chromium Coronary Stent System. The Company expects to launch the ION Stent System in the United States by mid2011. The TAXUS Element Stent System received CE Mark approval in Jun 11, 2010  June 11, 2010 A new drugeluting stent (DES) was launched this week in the European Union and other CE mark countries. The Taxus Element PaclitaxelEluting Coronary Stent System is Boston Scientifics thirdgeneration DES technology and incorporates a platinum chromium alloy with a new stent design and catheter delivery system. PROMUS Element Plus EverolimusEluting Platinum Chromium Coronary Stent System SYNERGY EverolimusEluting Platinum Chromium Coronary Stent System Promus PREMIER EverolimusEluting Platinum Chromium Coronary Stent System

Rating: 4.37 / Views: 764

A list of my favorite links


2020 © persrero.tk | Sitemap